I’d buy this FTSE 100 share, down 35% in the stock market crash

Shares in this world-class firm are near a nine-year low, but Cliff D’Arcy believes it will survive and grow after this stock market crash.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Last week, I read a cautionary commentary in the Financial Times. This warned that the coronavirus-induced stock market crash could get worse before it gets better. It urged investors to look for survivors – rather than winners – for their share portfolios.

This reminded me of a remark from legendary investor Warren Buffett. The Oracle of Omaha argues that two key criteria should drive investors’ buying decisions. First, the quality of the business they are buying and, second, its current share price.

This led me to the financials of one high-quality company: Johnson Matthey (LSE: JMAT). While hardly a household name, this British business is a long-time member of the blue-chip FTSE 100, currently valued at just £3.75 billion.

As a world leader in specialist chemicals and precious metals, Johnson Matthey has a track record in scientific innovation dating back to 1817. Its outputs are used in the production of industrial chemicals, emissions controls, batteries, and medical and pharmaceutical products.

Its shares have suffered in the stock market crash

A year ago, long before the coronavirus ravaged stock markets, Johnson Matthey’s market value was almost twice its current level. In 2020, its shares are down more than a third (36% at the time of writing), which I argue puts them firmly in the FTSE 100’s bargain bucket.

Indeed, their recent decline leaves Johnson Matthey shares close to a nine-year low. I feel this is a once-in-a-decade opportunity to buy into a British success that will keep growing long after Covid-19 is history.

Bouncing back after the coronavirus is beaten

Now for the all-important financials. In 2018/19, total revenues reached £10.7 billion, higher than in any year except 2016/17. This produced a pre-tax profit of £488 million, the highest since 2014/15. Put simply, after a blip in 2017/18, this solid business resumed its long-term growth path.

Adjusted earnings of 228.8p in 2018/19 covered the 85.5p dividend a tidy 2.67 times. At the current share price of £19.72, this puts Johnson Matthey shares on a price-to-earnings ratio of 8.6 and a dividend yield of 4.3%.

These are attractive numbers for income and value investors alike. However, in a recent trading statement in the midst of the stock market crash, the board warned that Covid-19 disruption could knock £50 million from its trading performance. The firm has responded by cutting costs and maximising cash flow.

This is a Buffett business selling cheaply

In short, Johnson Matthey is a 203-year-old British success story. It operates a high-quality portfolio of diverse businesses, backed by a strong balance sheet and good access to liquidity to trade through these troubled times. Yet this stock market crash has crushed its shares, presenting an attractive buying opportunity for Buffett fans!

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Cliff D'Arcy has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »